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Abstract
Respiratory syncytial virus (RSV) is the major cause of viral lower respiratory tract illness in
children. In contrast to the RSV prototypic strain A2, clinical isolate RSV 2–20 induces air-
way mucin expression in mice, a clinically relevant phenotype dependent on the fusion (F)
protein of the RSV strain. Epidermal growth factor receptor (EGFR) plays a role in airway
mucin expression in other systems; therefore, we hypothesized that the RSV 2–20 F protein
stimulates EGFR signaling. Infection of cells with chimeric strains RSV A2-2-20F and A2-2-
20GF or over-expression of 2–20 F protein resulted in greater phosphorylation of EGFR
than infection with RSV A2 or over-expression of A2 F, respectively. Chemical inhibition of
EGFR signaling or knockdown of EGFR resulted in diminished infectivity of RSV A2-2-20F
but not RSV A2. Over-expression of EGFR enhanced the fusion activity of 2–20 F protein in
trans. EGFR co-immunoprecipitated most efficiently with RSV F proteins derived from
“mucogenic” strains. RSV 2–20 F and EGFR co-localized in H292 cells, and A2-2-20GF-
induced MUC5AC expression was ablated by EGFR inhibitors in these cells. Treatment of
BALB/c mice with the EGFR inhibitor erlotinib significantly reduced the amount of RSV A2-
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2-20F-induced airway mucin expression. Our results demonstrate that RSV F interacts with
EGFR in a strain-specific manner, EGFR is a co-factor for infection, and EGFR plays a role
in RSV-induced mucin expression, suggesting EGFR is a potential target for RSV disease.
Author Summary
Respiratory syncytial virus (RSV) is responsible for severe lower respiratory disease in
infants and young children. Overabundant airway mucus contributes to airway obstruc-
tion in RSV bronchiolitis, and a better understanding of RSV pathogenesis may contribute
to needed therapies and vaccines. We reported previously that RSV clinical isolate strain
2–20 induces more airway mucin expression in mice than prototypic RSV strains and that
the 2–20 fusion (F) protein mediates mucin induction. Epidermal growth factor receptor
(EGFR) has been shown to play a role in lung mucin expression. We identified a functional
interaction between 2–20 F and EGFR, in that 2–20 F expression activated EGFR and,
reciprocally, EGFR expression increased 2–20 F fusion activity. RSV F and EGFR co-local-
ized in infected cells. EGFR co-immunoprecipitated with RSV F protein from various RSV
strains, and the strength of this in vitro interaction correlated with strain-specific airway
pathogenicity in mice. EGFR inhibition abrogated 2–20 F-mediated infection in vitro and
mucin expression induction in vivo. These data identify EGFR as a novel strain-specific
co-factor of RSV infection and suggest EGFR may be a target for ameliorating RSV
disease.
Introduction
Respiratory syncytial virus (RSV) is a human pathogen of the Pneumovirus genus within the
Paramyxoviridae family. Worldwide, the virus causes over 30 million lower respiratory tract ill-
nesses per year in children and is a leading cause of infant pneumonia mortality [1, 2]. Despite
a substantial clinical burden of disease, there are no available vaccines or RSV-specific thera-
peutics. A challenge to RSV vaccine and therapy strategies remains elucidation of the unclear
relationship between RSV infection and pathogenesis.
RSV is an enveloped, non-segmented, negative-strand RNA virus whose genome is approxi-
mately 15.2 kb in length and encodes 10 genes which are translated into 11 proteins. RSV
attachment is mediated through host glycosaminoglycans (GAGs), cellular protein nucleolin,
association with cholesterol-rich microdomains, and CX3CR1 [3–9]. Mechanisms surrounding
RSV entry remain unclear and other host receptors, co-receptors, and co-factors contributing
to infection are likely to be identified. Two envelope proteins mediate RSV infection, the
attachment glycoprotein (G) and the fusion (F) protein. Prior to infection, RSV F exists in a
metastable pre-fusion conformation [10, 11]. RSV F undergoes a series of conformational
changes yielding a thermodynamically stable six-helix post-fusion bundle, which drives viral
and host membrane fusion [11–13]. RSV G is mucin-like, having extensive N- and O-linked
glycosylation, and G is responsible for facilitating RSV attachment through interactions with
GAGs and CX3CR1 [4, 6, 7, 9, 14, 15]. However, G is not absolutely required for viral entry
into immortalized monolayer cells [16–18]. Mechanisms by which F and G mediate host cell
entry and their interactions with other host cell targets remain uncertain.
Epidermal growth factor receptor (EGFR) is a host glycoprotein comprised of an extracellu-
lar ligand receptor and intracellular kinase domain. The latter is activated through both Src-
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dependent phosphorylation and autophosphorylation [19, 20]. In addition to a wide variety of
host ligands including epidermal growth factor (EGF) and transforming growth factor alpha
(TGFα), several viruses have been identified that employ EGFR binding and activation for viral
entry and replication. These pathogens include hepatitis B virus, human cytomegalovirus
(hCMV), and Epstein-Barr virus (EBV) [21–23]. Previous studies by others evaluating the role
of EGFR in RSV infection have shown that RSV activates EGFR in lung epithelial cells [24, 25].
EGFR activation in these cells promotes a pro-inflammatory response including increased sur-
vival of RSV-infected cells and suppression of interferon regulatory factor (IRF) 1-dependent
CXCL10 production, an important event for recruitment of lymphocytes to infected airway
epithelial cells [24, 25]. Another study using a recombinant virus based on the RSV subgroup
A prototypic strain A2 demonstrated that RSV cell entry is largely mediated through endocy-
totic macropinocytosis promoted by EGFR phosphorylation [26].
Respiratory failure is the critical consequence of RSV disease in children, and overabundant
mucus obstruction of the airways contributes to this outcome. Our laboratory previously
reported that clinical isolate RSV A2001/2-20 (2–20) causes more airway necrosis, inflamma-
tion, and mucin expression during infection in BALB/cJ mice than the A2 reference strain [27,
28]. Transfer of the RSV 2–20 F protein into strain A2 recapitulated higher levels of airway
mucin expression in mice [28]. These studies demonstrated that the RSV F protein plays a key
role in airway epithelium infection and pathogenesis in vivo and suggests that RSV F plays a
role in RSV strain-specific phenotypes. EGFR phosphorylation is known to play a role in
mucin expression in airway epithelial cells during influenza and rhinovirus infections [29, 30].
We hypothesized that mucin induction by RSV 2–20 F is mediated by a specific interaction
with EGFR. To test this hypothesis, we evaluated the ability of A2 and 2–20 viruses and tran-
siently expressed F proteins to activate EGFR, and we assessed the impact of disrupting these
interactions on virus infectivity in vitro and mucin expression in vivo. We demonstrate that
RSV 2–20 F protein specifically binds to and activates EGFR, EGFR contributes to RSV-2-20 F
infectivity, and EGFR signaling mediates 2–20 F induction of airway mucin expression in mice.
Results
RSV 2–20 F activates EGFR, and EGFR promotes 2–20 F protein
activity
As EGFR phosphorylation/activation mediates mucin expression in response to other respira-
tory viruses, RSV A2 is known to activate EGFR, and RSV 2–20 F is more “mucogenic” than
A2 F in the context of infection, we hypothesized that the 2–20 strain F protein potently acti-
vates EGFR. Western blotting was performed to determine levels of total EGFR and phospho-
EGFR (p-EGFR) after infection of HEp-2 cells with RSV strains A2 and A2-2-20F. We used
serum-starved cells because serum is an activator of EGFR signaling in vitro [31, 32]. A2-2-
20F-infected cells had a higher ratio of p-EGFR to EGFR than A2-infected cells at 24 h post-
infection (Fig 1A). We performed similar experiments in serum-starved NCI-H292 (H292)
cells, and in an earlier time course we found that A2-2-20F infection resulted in a higher p-
EGFR/EGFR ratio than A2 infection at 1, 12, and 24 hr post-infection (Fig 1B). To define the
role of RSV 2–20 F expression alone in EGFR activation, A2 F and 2–20 F expression con-
structs were transfected into serum-starved HEp-2 cells and blotted for EGFR and p-EGFR lev-
els. There was a significantly higher 4.45-fold ratio of p-EGFR to EGFR after 2-20F expression
than after A2 F expression (Fig 1C). These data demonstrate that the 2–20 RSV F protein acti-
vated EGFR in cells to a greater extent than the A2 strain F protein.
We tested whether EGFR can enhance RSV F protein fusion activity. We used a previously
established cell-cell fusion assay [28, 33, 34]. The dual-split protein (DSP) assay is based on co-
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transfecting an “effector”/cis population of 293T cells with a construct expressing N-terminal
domains of a Renilla luciferase and GFP fusion protein (DSP1-7) and an F expression construct
in the presence of specific fusion inhibitor. Another population of 293T cells (“target”/trans) is
transfected with a construct expressing the C-terminal domains of the luciferase-GFP fusion
protein (DSP8-11) and, in this case, either equal molar amounts of empty vector (pcDNA) or an
EGFR expression vector. The fusion inhibitor is washed out, the effector and target cells are
mixed, and fusion is quantified by luciferase activity reconstituted by cell content mixing. A2 F
Fig 1. RSV 2–20 F activates EGFR and vice versa. (A) Representative total EGFR and p-EGFRWestern blots from serum-starved HEp-2 cells 12
and 24 hr after infection at an MOI = 3 with RSV A2 or A2-2-20F. Mock infection and FBS were controls. Densitometry of four experimental replicates
providing the ratio of detected p-EGFR to EGFR is shown below. (B) Total and p-EGFR levels from serum-starved H292 cells 0, 0.5, 1, 12, and 24 hr
after infection at MOI = 3. (C) Representative EGFR and p-EGFRWestern blots from serum-starved HEp-2 cells 24 h after transfection with vectors
expressing A2 F or 2–20 F protein. Quantification of the ratio of detected p-EGFR to EGFR from three experiments is shown at right. (D) Cell-cell
fusion activity was quantified by the DSP assay as described in the text and Materials and Methods. Cell-cell fusion was measured 4, 6, and 8 h after
mixing effector and target cells. (E) Cell-cell fusion 12 and 16 h after cell mixing following transfection with EGFR in either the same effector cells (cis)
as 2–20 F or in the target (trans) cells. Error bars represent standard error of the mean (SEM). * and ** represent significant differences (P < 0.05 and
P < 0.005, respectively by ANOVA). Graphs in (C) and (D) depict three experimental replicates combined.
doi:10.1371/journal.ppat.1005622.g001
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had significantly more cell-cell fusion activity than 2-20F in this assay (Fig 1D). Expression of
EGFR in trans enhanced 2–20 F activity but not A2 F activity (Fig 1D). Similar to published A2
F and 2–20 F fusion assay experiments [28], we found no difference, as measured by flow
cytometry, between A2 F and 2–20 F surface expression in 293T cells (S1 Fig). To determine
whether the boost in RSV 2-20F fusion is specific to a trans F-EGFR interaction, 2-20F was
either co-expressed (in cis) with EGFR or in trans in the target cells. There was a significant
boost to 2-20F fusion when EGFR was expressed in trans but not in cis, suggesting EGFR
enhancement of 2–20 F activity does not occur when the proteins are overexpressed in the
same cells or membrane (Fig 1E). Co-expression of EGFR with RSV F did not alter F surface
expression (S1 Fig). There was no effect on 2–20 F activity by overexpression of signaling lym-
phocyte activation molecules (SLAM), a receptor for measles virus (MeV) serving as an irrele-
vant transmembrane protein control. Collectively, the data show EGFR specifically enhanced
the fusion activity of RSV strain 2–20 F protein but not A2 F protein.
EGFR inhibition and knockdown reduced infectivity of RSV expressing
2–20 F
EGFR can function as receptor, co-receptor, or entry co-factor for other viruses, and EGFR
depletion in HeLa cells was reported to reduce RSV A2 strain infectivity [26]. We explored the
role of EGFR in RSV-2-20F infection. Cells were pre-treated with EGFR tyrosine kinase inhibi-
tors (AG1478 and PD153035) then infected with recombinant RSV A2, RSV A2-2-20F, or RSV
A2-2-20GF. Virus infectivity was measured by flow cytometry of virally expressed mKate2.
NCI-H292 (H292) cells are a human tracheal epithelial cell line known to express mucin genes
through activation of the EGFR pathway and known to support RSV replication [35–37].
Treatment of H292 cells with increasing concentrations of EGFR inhibitor AG1478 resulted in
a dose-dependent reduction in infectivity of all three virus strains at an MOI of 1, and the
reduction in infection was greater against A2-2-20F and A2-2-20GF than against A2 (Fig 2A).
Treatment of H292 cells prior to RSV A2 infection at a higher MOI = 3 with either AG1478 or
PD153035 resulted in no change in infection (Fig 2B). In contrast, EGFR inhibition prior to
A2-2-20F or A2-2-20GF infection at MOI = 3 reduced infection efficiency (Fig 2B). Treatment
in BEAS-2B cells, a human bronchial epithelial cell line, with AG1478 or PD153035 resulted in
similar decreases in infectivity of RSV A2-2-20F and A2-2-20GF while having no effect on A2
(Fig 2B). In order to test the effect of EGFR inhibition on RSV infectivity in a model more rele-
vant to RSV biology, we utilized normal human bronchial epithelial cells differentiated at air-
liquid interface (NHBE-ALI) [38]. We found that pre-treatment of NHBE-ALI cultures with
5 μMAG1478 was not toxic, as previously described, whereas PD153035 was toxic to
NHBE-ALI [39]. Pre-treatment of NHBE-ALI cultures with AG1478 resulted in significant
reduction in infectivity of RSV A2-2-20F and A2-2-20GF, and no significant effect on A2 com-
pared to vehicle (Fig 2C). Taken together, EGFR signaling mediated infection by RSV express-
ing the 2–20 F protein.
To determine the role of EGFR expression in RSV infectivity, BEAS-2B cells were first trans-
duced with lentivirus expressing either EGFR-specific shRNA or scrambled (control) shRNA.
EGFR shRNA reduced expression of EGFR in BEAS-2B cells by 56% compared to the scram-
bled shRNA control (Fig 3A and 3B). shRNA knockdown of EGFR in BEAS-2B cells resulted
in lower infectivity of A2-2-20F and A2-2-20GF but not A2 (Fig 3C). MeV infection is known
to be EGFR-independent; therefore MeV was used as a control for RSV specificity [40]. The
knockdown data show EGFR acted as a co-factor contributing to infectivity of RSV expressing
the F protein of the clinical isolate 2–20 and suggest RSV F may be interacting with EGFR in a
strain-dependent manner.
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Fig 2. EGFR Inhibition Results in Reduced Infectivity of RSV A2-2-20F and A2-2-20GF. (A) Serum-starved H292 cells were pre-treated for 1 h
with DMSO vehicle or the indicated concentrations of AG1478 prior to infection with RSV A2, A2-2-20F, or RSV A2-2-20GF at an MOI of 1.
Following 24 h of infection in the presence of inhibitor, cells were harvested and evaluated for infection by flow cytometry for mKate2 expression.
The percent infectivity was normalized to infectivity of the strain in vehicle treatment. (B) Serum-starved H292 (left) or BEAS-2B (right) cells were
pre-treated with either 10 μMAG1478 or 400 nM PD153035 and infected as described with the indicated RSV strains at MOI = 3. (C) NHBE-ALI
cultures were pre-treated with 5 μMAG1478 then infected with the indicated RSV strains at MOI = 3. Error bars represent standard error of the
mean (SEM). *, **, and *** represent significant differences (P < 0.05, P<0.005 and P < 0.0005, respectively by ANOVA) between the drug
treatment conditions compared to A2 infection. Graphs in (A), (B), and (C) represent three experimental replicates combined.
doi:10.1371/journal.ppat.1005622.g002
Fig 3. Knockdown of EGFR in BEAS-2B Cells Results in RSV Strain-Specific Reduction of Virus Infection. (A–B)
BEAS-2B cells were treated with scrambled (Control) shRNA or EGFR-specific shRNA by lentivirus transduction.
Representative images of reduction in EGFR expression detected byWestern blot (A) probing for EGFR and by flow
cytometry (B) are shown. Quantification of the flow cytometry data from two experimental replicates is shown. (C) BEAS-
2B cells treated with EGFR-specific shRNA were infected with RSV A2 (black), A2-2-20F (blue), A2-2-GF (green), or
GFP-MeV (orange), and infection evaluated by flow cytometry. Representative images are shown on the left and
quantification of three experimental replicates on the right. Error bars represent standard error of the mean (SEM) and *
represents significant differences (P < 0.05 by ANOVA) compared to A2 infection.
doi:10.1371/journal.ppat.1005622.g003
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RSV F binds EGFR and the extent of binding is RSV strain-specific
We assessed whether a physical (direct or indirect) interaction can occur between overex-
pressed RSV F and EGFR. 293T cells were transfected with either EGFR or SLAM and RSV F.
All proteins were detected at high levels in whole cell lysates (Fig 4A). RSV F was immunopre-
cipitated (IP) well with motavizumab mAb and probed for the presence of co-precipitated
EGFR. Motavizumab binds an epitope in RSV F that is conserved among RSV strains and
between the prefusion and postfusion conformations of the protein [41, 42]. EGFR was
detected after precipitation of A2F and 2-20F, and there was a 2.8-fold higher ratio of EGFR
bound to 2-20F than to A2F (Fig 4B). We previously deposited the 2–20 genome sequence to
GenBank and have modeled the residue differences between A2 F and 2–20 F [27]. To identify
putative EGFR interaction sites for RSV 2–20 F, three sets of mutations were introduced into
2–20 F that changed amino acids to the corresponding A2 residues. Mutation sets were intro-
duced into the F head region (T63N, E66K, and G76I triple mutant), stalk region (G519V and
K524N double mutant), and in the cleaved 27 residue peptide (pep27) between the furin cleav-
age sites (N124K) of 2–20 F. Introduction of either the head or the stalk mutation sets resulted
in reductions in the efficiency of EGFR-bound to 2–20 F, as detected by IP (Fig 4B). The
N124K pep27 mutation did not affect the co-IP efficiency significantly (Fig 4B). Taken
together, residues 63/66/76 and residues 519/524 contributed to the co-IP interaction between
2–20 F and EGFR.
We evaluated the Co-IP interaction of F proteins from other RSV strains with EGFR. Strain
Line 19 is a laboratory strain that that is more pathogenic in mice, including high viral loads,
lung IL-13 levels, and airway mucin expression in BALB/c mice, compared to prototypic
strains A2 and Long [43, 44]. RSV strain A2001/3-12 (3–12) is a clinical strain we previously
reported to induce lower airway mucin expression in mice than 2–20 [27]. Similar to 2–20,
overexpression of line19 F resulted in higher efficiency of EGFR co-IP than did overexpression
of A2 F, Long F, or 3–12 F (Fig 4B) The data correlate strength of co-IP F-EGFR interaction in
vitro with in vivomucogenicity in mice of the strain from which F was derived.
Co-localization of RSV F and EGFR in cells
We quantified molecular co-localization between EGFR and RSV F at the cell surface. H292
cells were inoculated with either mock, A2, A2-2-20F, or A2-2-20GF at 4°C, which facilitates
attachment but not viral fusion. After one hour and washes, the cells were fixed and stained for
RSV F and EGFR then examined by superresolution microscopy at the plasma membrane.
There was no significant overlap between EGFR and RSV F puncta in the A2 strain group (Fig
5A and 5B). In contrast, there was significant overlap between RSV F and EGFR puncta on the
surface of A2-2-20F- and A2-2-20GF-inoculated cells (Fig 5A and 5B). There were more RSV
F puncta per cell in the A2-2-20GF group than the A2-2-20F and A2 groups, consistent with
published data that 2–20 G has greater attachment activity than A2 G (Fig 5A) [18]. A2-2-
20GF attachment also resulted in greater co-localization of F and EGFR than A2-2-20F (Fig 5A
and 5B), suggesting the 2–20 G protein also directs RSV localization at the cell surface. Taken
together, there was significant co-localization between 2–20 F and EGFR at the cell surface fol-
lowing virus attachment, which was enhanced by 2–20 G.
To evaluate whether RSV co-localizes with EGFR in a highly relevant primary airway epithe-
lium model, well-differentiated primary pediatric bronchial epithelial cells (WD-PBECs) [45]
were analyzed for surface expression of p-EGFR. RSV BT2a induces mucus secretion and goblet
cell hyperplasia/metaplasia inWD-PBECs [45]. p-EGFR expression inWD-PBEC cultures was
largely focused in the cell membrane on ciliated structures as evidenced by co-localization with
beta-tubulin (Fig 5C). WD-PBEC cultures were infected with clinical isolate, BT2a, which has
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Fig 4. EGFR Interaction with RSV F Depends on Strain-Specificity of F. 293T cells were co-transfected
with either SLAM (control) or EGFR and RSV F constructs. Whole cell lysates were obtained after 24 h post-
transfection and were either directly blotted (A) or immunoprecipitated with motavizumab mAb specific for
RSV F (B). Whole cell lysates were probed for RSV-F, EGFR, SLAM, and vinculin expression. Proteins
immunoprecipitated were probed for RSV-F and EGFR levels. The graph depicts ratios of EGFR to RSV F1
from four separate experiments combined. Error bars represent standard error of the mean (SEM). * and **
represent significant differences (P < 0.05 and P < 0.005, respectively by ANOVA).
doi:10.1371/journal.ppat.1005622.g004
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Fig 5. RSV F Co-localizes with EGFR in H292 andWD-PBECs. (A) Representative 3D superresolution microscopy images of H292 cells inoculated
with A2, A2-2-20F, or A2-2-20GF at 4°C and MOI = 3 then fixed and stained for EGFR and RSV F at the cell surface. Magenta puncta show EGFR
staining, green puncta show RSV F staining, and white shows EGFR/F overlap. The scale bar represents 5 μm. (B) Quantification of EGFR signal
overlap with RSV F signal on the surface of 10 different cells infected with each virus. Error bars represent standard error of the mean (SEM). * and
*** represent significant differences (P < 0.05 and P < 0.0005, respectively by ANOVA). (C) Representative WD-PBEC cultures were fixed with PFA
and permeabilized before being stained for p-EGFR (red) and beta-tubulin (β-tubulin, green). Images were visualized by confocal microscopy. (D and
E) WD-PBEC cultures were infected with RSV clinical isolate BT2a and stained for EGFR (red) and RSV F (RSV F, green) expression.
doi:10.1371/journal.ppat.1005622.g005
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similar kinetics to A2 during infection in HEp-2 cells, but exhibits more cytopathogenesis in
WD-PBEC cultures [45]. Many cells infected with clinical isolate BT2a qualitatively co-localized
with p-EGFR (Fig 5D). Interestingly, infection of WD-PBECs with BT2a resulted in an apparent
increase in surface expression of p-EGFR in RSV-infected cells, but not neighboring non-infected
cells (Fig 5E). Collectively, the co-localization data suggest RSV F is closely associated with EGFR
at the plasma membrane of H292 and apically in human primary airway epithelial cells.
Infection of the airway epithelium of mice by RSV A2-2-20F
Infection of BALB/cJ mice with RSV A2-2-20F or the parental isolate 2–20 results in airway
mucin expression that peaks approximately day 8 post-infection, a time point when infectious
virus is not detectable by plaque assay [27, 28]. We previously demonstrated that 2–20 infects
the mouse airway epithelium, detectable by immunofluorescence day one post-infection [27].
We examined whether A2-2-20F also infects the mouse airway epithelium and whether virally
expressed proteins can be detected in PAS-positive airways. Mice were mock-infected or
infected with A2-2-20F that does expresses mKate2 or A2-2-20F lacking the mKate2-encoding
gene. The mKate2 far-red fluorophore has extreme pH stability [46], therefore we hypothesized
it will remain functional after histology processing. When adjacent, serial lung sections were
compared, mKate2 signal was evident day 8 post-infection in bronchial epithelium that was
also producing mucin (Fig 6). To control for autofluorescence, lung sections from recombinant
Fig 6. Virally-expressed protein in mucin producing bronchial epithelium. BALB/cJ mice were mock-infected or infected with A2-2-20F (-mKate2)
or A2-2-2-20F. Lungs were harvested day 8 post-infection. Serial lung sections were processed for PAS staining or deparaffinized, rehydrated, and
DAPI stained. PAS staining shows mucin producing cells (left column). The mKate2 signal was detected by fluorescence microscopy in the adjacent
lung section (middle column). A gray level display of the DAPI channel (right column) shows tissue architecture of the mKate2+DAPI section (middle
column). Yellow bar represents 100μm.
doi:10.1371/journal.ppat.1005622.g006
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A2-2-2F that does not express mKate2 infected and mock-infected mice were also examined.
The mKate2 signal was clearly distinguishable from background (Fig 6), marking cells that
were either previously infected and harboring mKate2 or cells actively expressing RSV-encoded
gene products. These results correlate A2-2-20F infection with airway mucin expression.
Inhibition of EGFR ablates RSV A2-2-20F-induced airway mucin
expression in mice
Muc5ac is a major inducible and secreted mucin protein in the lung that is up-regulated by
EGFR activation and during RSV infection [43, 47–49]. We first tested whether RSV infection
of these cells results in MUC5AC gene expression. In DMSO-treated serum-starved H292 cells,
A2-2-20GF infection resulted in higher MUC5AC mRNA levels than mock, A2, and A2-2-20F
infection (Fig 7A). Therefore H292 cells provide an in vitromodel of RSV strain-specific induc-
tion of mucin expression. Serum-starved H292 cells were treated with EGFR pathway inhibi-
tors PD153035 and AG1478, mock-infected or infected with RSV strains A2, A2-2-20F, and
A2-2-20GF, and MUC5AC expression was quantified. In the presence of either inhibitor,
MUC5AC mRNA fold-change in A2-2-20GF infected cells was ablated. The combination of
RSV 2–20 F and 2–20 G was important for MUC5AC induction in this in vitromodel, consis-
tent with the efficient attachment function of 2–20 G (Fig 5A and ref [18]), and the EGFR path-
way was critical for MUC5AC induction.
We tested the role of EGFR signaling in A2-2-20F-induced airway mucin expression.
BALB/cJ mice were pre-treated with erlotinib, a specific quinazoline derivative that binds to
and inhibits EGFR tyrosine kinase activity, or vehicle suspension, and tested for suppression of
EGFR activation in mouse lung homogenates [50]. Erlotinib caused a reduction in the signal of
p-EGFR in lungs from both mock-infected and A2-2-20F-infected mice (Fig 7B). Mice pre-
treated then treated daily with vehicle or erlotinib were infected with mock or A2-2-20F. Lungs
were harvested day 8 post-infection and processed for periodic acid-Schiff (PAS) stains of gob-
let cell hyperplasia/metaplasia (Supplemental Fig 2), a surrogate of airway for mucin expres-
sion. Our lab uses a digital pathology system to morophometrically quantify PAS positivity in
all airways involved in lung sections [27, 28]. Mice treated with erlotinib and infected with A2-
2-20F had significantly less airway goblet cell hyperplasia/metaplasia than vehicle-treated, A2-
2-20F-infected mice (Fig 7C and 7D). Taken together, these data identify a novel role for EGFR
signaling in mediating RSV-induced mucin expression and airway pathology.
Discussion
RSV disease in infants is associated with airway obstruction, lung inflammation, epithelial cell
sloughing, and mucus production [51, 52]. The relative contributions of sloughed epithelium
and mucus production to airway obstruction remain unknown [53, 54]. Distal airways are
thought to have fewer mucin-secreting cells than larger airways, but overabundant mucus pro-
duction is associated with infant bronchiolitis clinically [53–55]. The clinical isolate strain 2–20
to a degree recapitulates human RSV disease in the BALB/c mouse model of RSV infection [27,
28, 56]. The prototypical A2 strain does not cause airway mucin expression in mice, and chime-
ric RSV strains A2-2-20F is mucogenic like parental 2–20, implicating the F protein in mucin
induction in vivo [28, 44]. RSV 2–20 has somewhat altered tropism in the mouse because it
infects the airway epithelium and alveolar epithelial cells, whereas A2 infects predominantly
alveolar epithelial cells [27]. 2–20 and A2-2-20F cause more airway necrosis in mice than A2
[28]. Therefore, infection of the mouse airways correlates with mucin induction in this model.
Here, we investigated mechanisms of 2–20 F-induced airway mucin induction. In cultured cells,
2–20 F exhibited greater functional and physical interaction with EGFR than A2 F, and EGFR
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was able to enhance the fusion activity of the 2–20 F protein. Chemical inhibition of EGFR sig-
naling reduced infectivity of 2–20 F-expressing RSV and ablated mucin induction in vitro and in
vivo. We report that RSV F interacts with and activates EGFR and that EGFR contributes to
infection in vitro and plays a critical role in RSV-induced mucin expression.
Fig 7. Inhibition of EGFR ablates RSV-inducedmucin expression in vitro and in mice. (A) H292 cells pre-treated with DMSO, 400
nM PD153035, or 10 μMAG1478 were infected with A2 (black), A2-2-20F (blue), or A2-2-20GF (green) at MOI = 1. MUC5ACmRNA
levels were quantified by real-time PCR. The fold change relative to mock infection and vehicle-treated cells is shown. (B—D) BALB/cJ
mice were pre-treated and treated daily with 100 mg/kg erlotinib, an EGFR inhibitor, or vehicle prior to mock infection or 106 PFU A2-2-
20F. Lungs were harvested day 8 post-infection. (B) Total and P-EGFR levels in lung homogenates. (C) Representative lung sections
stained with PAS. (D) Quantification of the percentage of the area of each airway staining positive in treatment groups. Each symbol
represents a single airway and there were at least 285 individual airways from 5 mice shown for each treatment group. One of two
replicate experiments with similar results is depicted. * represents a significant difference (P < 0.05 by ANOVA) between vehicle and
erlotinib treatment.
doi:10.1371/journal.ppat.1005622.g007
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Our study shows F and EGFR interact functionally and physically. Expression of the 2–20 F
protein potently activated EGFR, as measured by p-EGFR levels in cells. The efficiency of co-IP
of EGFR with F depended on strain specificity of the expressed F protein. EGFR had the highest
co-IP efficiency with 2–20 and line 19 F proteins, strains previously shown to be mucogenic in
mice [27, 28, 44]. We mapped the enhanced co-IP efficiency with 2–20 F to two domain differing
between 2–20 F and A2 F, residues 63/66/76 and residues 519/524. Amino acids 63, 66, and 76
cluster at the top of the prefusion F trimer. This region overlaps prefusion-specific antigenic site
;, and the adjacent residue 67 is important for RSV F prefusion stability [11, 57]. As we discussed
in Stokes et al, residues 519 and 524 in RSV F are membrane-proximal in the stalk, a region
implicated in regulating Hendra virus F protein triggering via stabilization of the pre-fusion form
[28, 58]. In our co-IP experiments, we expressed functional F, which for RSV does not require
triggering by the attachment protein, so prefusion and postfusion forms were present. We specu-
late that 63/66/76 and 519/524 regions regulate prefusion stability, which may relate to EGFR co-
IP efficiency between F species and mutants. In the DSP fusion assay, EGFR boosted 2–20 activ-
ity, so we predict the functional interaction occurs prior to postfusion F formation. Additional
studies and reagents will be required to further elucidate F-EGFR molecular interactions.
RSV infection was previously shown to activate EGFR. The A2 strain activates EGFR in
cells, resulting in delayed apoptosis by ERK activation and production of the pro-inflammatory
cytokine IL-8 production [24]. RSV A2 strain was shown to activate EGFR following virus
attachment, leading to macropinocytotic endocytosis [26]. In that study, EGFR depletion in
HeLa cells by siRNA delivery resulted in reduced infectivity of the A2 strain, whereas we found
that EGFR depletion in BEAS-2B cells reduced infectivity of RSV expressing 2–20 F but not of
the A2 strain. The discordant findings may be related to the cell line and/or the efficiency of
EGFR knockdown. Recently, RSV activation of EGFR, in addition to influenza A (H1N1) and
rhinovirus infections, led to suppression of IRF1-dependent CXCL10 production [25].
CXCL10 is expressed in airway epithelial cells, is a ligand of CXCR3 (a key regulator of leuko-
cyte trafficking), and when elevated is associated with obstructive airway diseases [25, 45, 59,
60]. Using RSV 2–20 F-expressing viruses in future studies may shed additional light on entry
mechanisms, such as macropinocytosis, and downstream immunopathogenesis such as IL-8
expression, neutrophil recruitment, and CXCL10 expression.
The capacity of RSV F to engage EGFR during infection may depend in part on a function
of the RSV G protein. We observed an appreciable increase in MUC5AC expression in H292
cells when using strain A2-2-20GF, not A2 or A2-2-20F. In these cells, 2–20 G conferred
greater attachment, as measured by superresolution microscopy, consistent with the sequence-
based prediction that 2–20 G has more glycosylation sites and our recent published data that
2–20 G has a higher apparent molecular weight than A2 G and confers enhanced cell attach-
ment in vitro [18]. The co-localization quantification in H292 cells revealed that, irrespective
of the abundance of RSV F puncta, 2–20 G greatly enhanced signal overlap between F and
EGFR, suggesting 2–20 G alters location of RSV on the plasma membrane. Our current work-
ing model is that initial 2–20 G interactions with CX3CR1, GAGs, and/or other factors medi-
ates attachment that likely precedes F-EGFR interaction, EGFR activation, and infection
(Fig 8). Further studies will need to evaluate the role of G in F-EGFR interactions during infec-
tion in cells and animal models.
In summary, we for the first time identified a host protein that both interacts with the RSV
F protein and promotes fusion. EGFR was expressed at the apical surface of differentiated pedi-
atric bronchial epithelial cells, and RSV F and EGFR co-localized in infected cells. Using clini-
cally relevant RSV strains and infection models, we found that EGFR is critical for RSV-
induced airway mucin expression and laid the groundwork for defining the molecular interac-
tion between F and EGFR.
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Materials and Methods
Ethics statement
All animal procedures were conducted according to the guidelines of the Emory University
Institutional Animal Care and Use Committee, under approved protocol number 2001533.
The study was carried out in accordance with recommendations in the Guide for Care and Use
of Laboratory Animals of the National Institute of Health, as well as local, state, and federal
laws.
Cells and reagents
The media components and origins of HEp-2, BEAS-2B, 293T, and BSR-T7/5 cells we use are
previously described [27, 28]. NCI-H292 cells were purchased from ATCC (CRL-1848) and
propagated in RMPI-1640 supplemented with 10% FBS (Hyclone, Thermo Scientific), 0.01 M
HEPES, and 25 mMD-glucose. Normal human bronchial epithelial (NHBE) cells were
obtained from Lonza (Allendale, NJ) and differentiated on collagen-coated 24-well transwell
supports at air-liquid interface as we described [38]. The human codon bias-optimized RSV A2
F and 2–20 F expression plasmids are described, and the RSV 2-20GF-expression plasmid was
generated using the same strategy [28]. EGFR cDNA in a pBABE retroviral vector was trans-
ferred into pTriEx-3 using standard restriction enzyme cloning to yield pTriEx-3-EGFR, and
the sequence of EGFR was confirmed. A full-length SLAM cDNA was extracted from Vero-
SLAM cells and cloned into the pCG expression plasmid. DSP1-7 and DSP8-11 plasmids were
provided by Naoyuki Kondo and Zene Matsuda [61]. Lipofectamine 2000 (Life Technologies)
was used according to the provided protocol for all cell transfections, with the exception that
DNA/liposome mixture remained on cells overnight for RSV rescue. The anti-RSV F mAb
motavizumab was generously provided by Nancy Ulbrandt (MedImmune AZ). Mouse anti-
SLAM was purchased from Abcam (clone ab2604) and mouse anti-vinculin was purchased
from Fisher Scientific (clone VLN01). HRP-conjugated secondary antibodies for
Fig 8. Model of RSV G and F interactions with host factors at the cell surface. (A) RSV Gmediates attachment by interacting with GAGs,
CX3CR1, and potentially other factor(s). RSV 2–20 G is more heavily glycosylated and confers greater cell attachment activity than A2 G, as indicated
by the width of the purple arrows. (B) RSV F interacts with EGFR, and RSV 2–20 F does so more strongly than A2 F (purple arrows). The F-EGFR
interaction contributes to infection, EGFR activation, and induction of mucin gene expression.
doi:10.1371/journal.ppat.1005622.g008
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immunoblotting were purchased from Jackson Immunoresearch. Compound AG1478 (LC
Laboratories) was diluted in DMSO. Recombinant human EGR was obtained from Lonza (Cat
#00556827).
Viruses
We previously reported generation of recombinant RSV encoding the far-red fluorescent pro-
tein monomeric Katushka-2 (mKate2) in the first gene position [62]. This virus was recovered
on BSR-T7/5 cells transfected with pSynkRSV-line19F BAC together with helper plasmids
encoding codon-optimized N, P, L, and M2-1 [62]. The F gene of BAC pSynkRSV-line19F,
flanked by SacII and SalI sites, was replaced with a synthetic cDNA (GeneArt, Life Technolo-
gies) encoding either the A2 strain F open reading frame, the 2–20 strain F open reading frame,
or the 2–20 strain G and F open reading frames, flanked by non-coding regions identical to
those in pSynkRSV-line19F BAC [18]. The recombinant A2-2-20F that does not encode
mKate2 (A2-2-20F –mKate2) was previously described [28]. The kRSV-A2, kRSVA2-2-20F,
and kRSVA2-2-20GF viruses were plaque-purified and amplified in HEp-2 cells. Virus stocks
used were sequence confirmed for the G and F genes and determined to beMycoplasma free
using the Venor GeMMycoplasma detection kit (Sigma-Aldrich). RSV clinical isolate BT2a
was used for infection of well-differentiated primary pediatric bronchial epithelial cells
(described below) [45]. Measles virus expressing GFP (MeV-GFP) used in this study was previ-
ously described [63].
EGFR knockdown
shRNA constructs targeting EGFR (TRCN0000039635, TRCN0000039634, TRCN0000039633,
TRCN0000010329, TRCN0000121067) were purchased from Sigma. The control plasmid
pLKO.1, which has a scrambled shRNA, was also purchased from Sigma. Two lentivirus helper
plasmids, psPAX2, and pMD2.VSVG, were kindly provided by Gregory Melikian (Emory Uni-
versity). Lentiviruses for the puromycin pLKO constructs were produced in 293T cells with
two helper constructs. 293T cells (6.5 × 105) were transfected with pLKO containing the EGFR
shRNA, psPAX2, and pMD2.VSVG. As a control, 293T cells were transfected with pLKO.1
containing a scramble shRNA. Supernatants were harvested at 24 h following transfection. For
infection, 30 to 40% confluent BEAS-2B cells were spinoculated with virus-containing superna-
tant at 4°C, 2900 x g. Following overnight incubation, media containing 1 μg/mL puromycin
was added for 48 hours post-infection. A kill curve of puromycin on BEAS-2B cells determined
that 1μg/mL puromycin killed 100% of cells. Surviving BEAS-2B cells following puromycin
treatment were used for RSV infection and subsequently used for determination of EGFR
knockdown efficiency.
Flow cytometry
Flow cytometry analysis was performed to quantify RSV infectivity and levels of EGFR surface
expression. Phycoerythrin-EGFR antibody (sc-101 PE, Santa Cruz) was used for the detection
of EGFR on non-permeabilized 293T or BEAS-2B cells using an LSRII flow cytometer (BD Bio-
sciences). Motavizumab and Alexa 488-anti-human secondary Ab (H17101, Life Technologies)
were used for measuring RSV F cell surface expression on non-permeabilized 293T cells.
BEAS-2B cells were harvested, fixed, and acquired using a 561nm laser. Isotype control anti-
body (PE-IgG) was used as a negative control. For measuring of RSV and MeV infectivity, cells
were harvested 24 hr post-infection and acquired using an LSRII, by detecting the mKate2 and
GFP signals, respectively. Data were analyzed using FlowJo software (TreeStar, Ashland, OR).
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RSV F protein co-ip and western blots
293T cells transfected with equal molar amounts of DNA were used for each group, and plas-
mid quality was checked via agarose gel and spectrophotometer quantitation. 24 h after treat-
ment, cells were harvested. Cell pellets were thawed on ice and lysed with RIPA buffer (Sigma)
plus protease inhibitors (Thermo Scientific). Protein concentrations were determined using
Bradford Reagent (Sigma). 50% (v/v) protein-A magnetic beads (Cell Signal) were conjugated
with motavizumab by mixing 50 μL of bead slurry with 500 μL ice cold PBS and 0.75 μg of
motavizumab (1.75 mg/mL) in a microcentrifuge tube rotating end-over-end for 4 h at 4°C.
Excess antibody was washed from the beads by pelleting, aspirating the antibody suspension,
and washing 3 times with 1 mL of RIPA buffer. 120 μL of cell lysate was pre-cleared with 30 μL
of non-conjugated bead slurry. 100 μL of cleared lysate was then added to the conjugated bead
pellet with 10 μL of 10% BSA (Sigma). The lysate/bead slurry was allowed to mix overnight,
rotating end over end at 4°C. Beads were removed using a magnetic tube rack on ice at 4°C,
were washed 4x in ice cold RIPA, and washed 1x in ice cold PBS. Beads were then pelleted by
and re-suspended in 3x SDS loading buffer. For Westerns, lysates or beads mixed with 3x SDS
loading buffer were heated 95°C 5 min then fractionated on 10% SDS-Page gels (Bio-Rad). Pro-
teins were transferred to PVDF membranes (Bio-Rad). Membranes were blocked with 2%
non-fat milk, 1% FBS (Gemini) in TBST. Membranes were incubated in primary antibody
overnight (p-EGFR, EGFR, or SLAM) or 2 h (motavizumab or vinculin).
Fusion assay
The dual-split protein (DSP) reporter cell-cell fusion assay was previously adapted to measur-
ing RSV F protein activity [28, 33, 34]. 293T “effector” (cis) cells were transfected with RSV A2
F or 2–20 F and DSP1-7 in the presence of fusion inhibitor BMS-433771 (a gift from Jin Hong,
Alios Biopharma, San Francisco, CA). 293T “target cells” (trans) were transfected with DSP8-11
and pCG-SLAM or pcDNA3.1 empty vector. Effector cis or target trans cells were transfected
with pTriex3-EGFR. Effector and target cells were washed with PBS 24 h post-transfection and
harvested by pipetting in media containing EnduRen live cell luciferase substrate (Promega).
Equal volumes of effector and target cells were mixed and placed into an opaque 96-well plate
in quadruplicate. Plates were incubated at 37°C and luciferase activity as a measure of cell-cell
fusion was assayed on a TopCount Luminescence counter (Perkin Elmer) 4, 6, and 8 h after
cell mixing. A positive control of DSP1-7 and DSP8–11 transfected into the same cell population
was used to validate replicates.
Real-time PCR
H292 cell monolayers were serum-starved for 24 h then mock-infected or infected with RSV.
The cells were washed with PBS and lysed with TRIzol reagent (Life Technologies) at 20 h
post-infection. Total RNA was isolated according to the TRIzol protocol. Quantitative real-
time PCR was performed using the AgPath-ID OneStep RT-PCR kit (Applied Biosystems) and
an ABI 7500 sequence detector system (Applied Biosystems). The primers and probes for
MUC5AC gene (forward, 50CGTGTTGTCACCGAGAACGT30; reverse, 50 ATCTT
GATGGCCTTGGAGCA 30, probe, 50 Fam- CTGCGGCACCACAGGGACCA-BHQ-1 30)
were obtained from Integrated DNA technologies (IDT) [64]. The primers and probes for
GAPDH, the control, were forward, 5’ GAAGGTGAAGGTCGGAGT 3’, reverse, 5’ GAA
GATGGTGATGGGATTTC 3’, and probe, 5’ Fam CAAGCTTCCCGTTCTCAGCC 3’.
Threshold cycles (Ct) and ΔCt for each sample was calculated. Assays were performed in dupli-
cate in 3 independent experiments.
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Immunofluorescence in H292 andWD-PBEC cells
H292 cells were cultured on 35-mm glass-bottom dishes (MatTek Corp). Cells were inoculated
at MOI = 3 at 4°C rocking for 1 h., conditions at which attachment but not fusion can occur,
washed twice in chilled PBS, and fixed in 10% buffered formalin (Thermo-Fisher) for 10
min. Cells were then washed 3X at room temperature with PBS. The fixed cells were blocked
overnight in serum-free protein block (Dako). Antibodies were diluted in an antibody diluent
with background reducing components (Dako). For the detection of RSV-F, a 1:2,000
dilution of 1.75 mg/mL motiavizmab was utilized. EGFR was detected with a rabbit polyclonal
(Millipore) used at a 1:500 dilution. Primary antibodies were allowed to bind to cells for 4 h
rocking at 4°C. Secondary antibodies anti-human IgG, IgA FITC conjugated (LifeTech) and
anti-rabbit Alexa-568 (LifeTech) were used at dilutions 1:5,000 and 1:2,000 respectively. Sec-
ondary antibodies were incubated for 1 h rocking at room temp, followed additional 3 wash
steps. Cells were kept at 4°C under PBS until imaging. Super-resolution images were acquired
using a DeltaVision OMX Blaze (GE Healthcare Life Sciences) for three-dimensional struc-
tured illumination microscopy (3D-SIM). 3D-SIM reconstructions were generated by soft-
WoRx (v6.1.3). The reconstructed files were further analyzed in Imaris (v8.1.2) where
appropriate channel thresholds were manually set. An overlap mask channel was created
using Imaris where the thresholded Mander's coefficient was calculated to quantify 3D
overlap.
For WD-PBECs, pediatric bronchial epithelial cells (PBEC) were obtained, via written
parental consent, from bronchial brushings of children undergoing elective surgery at the
Royal Belfast Hospital for Sick Children, and the procedures were approved by the Office of
Research Ethics Committees Northern Ireland [45]. PBEC were expanded in collagen-coated
flasks using airway epithelial cell media and supplements (Lonza), then seeded onto transwell
inserts (Corning), and then air-liquid interface (ALI) cultures were initiated and maintained 21
days in order to establish well-differentiated (WD)-PBECs, as described in further detail [45].
Paraformaldehyde-fixed and permeabilized WD-PBEC were stained for anti-β-tubulin,
MUC5AC, or RSV F protein expression as described [45] and were stained with anti-phospho-
(p)-EGFR (Abcam, ab40815). WD-PBEC cultures were infected with RSV subgroup A clinical
isolate BT2a as described [45]. Fluorescent images were obtained with a SP5 confocal DMI
6000 inverted microscope (Leica).
Erlotinib treatment of mice and quantification of airway mucin expression
7-week old female BALB/cJ mice (The Jackson Laboratory) were orally gavaged with 100 mg/
kg of erlotinib (Selleck Chemicals LLS, Catalog S1023) or vehicle (0.5% carboxymethylcellulose
/0.1% Tween 80) in a total volume of 100 μL daily, beginning two days prior to infection, and
continuing for the duration of the experiment. Mice were infected intranasally with 1 x 106
PFU of A2-2-20F or mock virus preparation. On day 8 post-infection, the lungs were harvested
and placed in 10% neutral buffered formalin for histopathology sectioning and periodic acid
Schiff (PAS) staining for goblet cell hyperplasia as a measure of airway mucin expression. PAS
positivity was quantified for greater than 285 individual airways total from 5 separate mice per
group by digital morphometric analysis as described previously [27]. In a separate group of
mice, the left lung was harvested, snap frozen, and later homogenized in RIPA buffer contain-
ing a protease inhibitor cocktail. The amount of total protein the lung homogenates was deter-
mined by Bradford assay and equivalent proteins from each group were loaded on a 4–17%
SDS-PAGE gel and separated by electrophoresis before Western blotting for total EGFR
(Abcam, AB15669) or p-EGFR Monoclonal (Abcam, AB24928).
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Fluorescent imaging of serial lung sections
7-week old female BALB/cJ mice (The Jackson Laboratory) were infected intranasally with 1 x
106 PFU of A2-2-20F (-mKate2), 1 x 105 FFU of A2-2-2-20F, or mock virus preparation. On
day 8 post infection, lungs were harvested and prepared as above for PAS staining or, after sec-
tioning, were deparaffinized with Clear-rite (Thermo Scientific), rehydrated through graded
alcohols to water, and then stained with Prolong DAPI Gold (Life Technologies). PAS slides
were imaged using a Mirax Imaging System as descried previously [27]. DAPI-stained slides
analyzed by fluorescence microscopy using the Mirax Image System. Equal exposure time was
used for each channel (DAPI 120μs, mKate2 900μs) across all groups. Excitation was provided
by HXP-120 light source (LEj) through Zeiss filter set 2 (DAPI) or 45 (mKate2). Images were
analyzed in Panoramic Viewer v1.15.2 (3DHISTECH), where pseudocoloring levels were kept
constant for each channel across all groups. Images of representative airways from the central
portion of each lung were exported as TIF files.
Supporting Information
S1 Fig. F and EGFR cell surface expression. 293T cells were transfected with EGFR and either
A2 F or 2–20 F. (A &B) Cell were harvested and (non-permeabilized) probed with mAbs to
either EGFR (A) or RSV F (B) and analyzed by flow cytometry. (C) The quantification of three
experiments combined showing that EGFR and RSV F surface expression do not vary between
cells transfected with EGFR and A2 F or EGFR and 2–20.
(TIF)
S2 Fig. Goblet cell hyperplasia/metaplasia resulting from RSV A2-2-20F infection. Lungs
from vehicle-treated and mock-infected (A-B) or RSV A2-2-20F-infected (C-D) mice were
harvested at day 8 p.i., serially sectioned, and stained with hematoxylin and eosin (H&E) (A
and C) or PAS (B and D). Arrows indicate goblet cells (C) and mucin (D). Magnification, 70 ×.
(TIF)
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